Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Sequential customized therapeutic keratectomy for Reis-Bücklers corneal dystrophy: long-term follow up

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Surface Photoablation

Session Date/Time: Sunday 06/09/2015 | 16:30-18:00

Paper Time: 16:54

Venue: Room 10

First Author: : R.Vinciguerra ITALY

Co Author(s): :    P. Vinciguerra   F. Camesasca   S. Trazza              

Abstract Details

Purpose:

To report long-term outcome of Sequential Customized Therapeutic Keratectomy (SCTK) for the treatment of Reis-Bücklers corneal dystrophy. Reis-Bücklers dystrophy involves the Bowman layer, progressively hinders visual acuity and causes recurrent erosions.

Setting:

Eye Center, Humanitas Clinical and Research Center, Rozzano, Italy

Methods:

SCTK is a therapeutic refractive treatment which entails the use of a multistep customized approach with sequential intraoperative topographies to achieve better results.Fourteen eyes of 9 patients with Reis-Bücklers corneal dystrophy underwent PTK surgery, followed by 0.02 % mytomicin application. Mean preoperative visual acuity was 0.44±0.22 LogMAR with mean correction of 0.14 D sph and -0.81 D cyl at 112°. Mean pupillary K was 42.67 D and mean pachimetry 554.62±29.81µ.

Results:

7.44±12.33 years after surgery, mean visual acuity was 0.78±0.24 LogMAR with mean correction of 0.75 D sph and -1.33 D cyl at 130°. Mean pupillary K was 43.08 D and mean pachimetry 536.20±58.03µ. Two eyes required retreatment, and no patient underwent corneal transplant.

Conclusions:

Seven years after SCTK, treated patients showed marked improvement in visual acuity, stability of refraction and recurrence of the disease requiring retreatment in only 14.2% of eyes. We recommend SCTK as a first-line treatment for Reis-Bücklers corneal dystrophy, before considering a more invasive approach.

Financial Interest:

NONE

Back to previous